Found 161 articles for: "ustekinumab"
Pipeline Previews
April 2015 | Volume 14 | Issue 4 | Features | 427 | Copyright © April 2015
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from the...
Read MoreNext-generation Biologics in the Management of Plaque Psoriasis: A Literature Review of IL-17 Inhibition
March 2015 | Volume 14 | Issue 3 | Original Article | 244 | Copyright © March 2015
Advances in the understanding of the pathogenesis of psoriasis have led to the development of biologic agents that target T cells and cytokines that play a specific role in the underlying inflammation...
Read MoreClearance of Psoriasis: The Impact of Private Versus Public Insurance
February 2015 | Volume 14 | Issue 2 | Original Article | 119 | Copyright © February 2015
BACKGROUND: Psoriasis treatments and therapeutic response as they relate to private versus public patient insurance in the United States have not yet been reviewed. Improved understanding could clarif...
Read MoreSystematic Review of Vismodegib Toxicity Profile in the Treatment of Advanced Basal Cell Carcinomas Compared to Other Systemic Therapies in Dermatology
June 2014 | Volume 13 | Issue 6 | Original Article | 729 | Copyright © June 2014
Vismodegib is a first-in-class, hedgehog-signal inhibitor that is FDA-approved for use with advanced basal cell carcinomas (BCCs) that cannot be removed by either surgical resection or treated with ra...
Read MorePipeline Previews
December 2013 | Volume 12 | Issue 12 | Features | 1492 | Copyright © December 2013
Immune Response to Pneumococcus and Tetanus Toxoid in Patients With Moderate-to-Severe Psoriasis Following Long-Term Ustekinumab Use
October 2013 | Volume 12 | Issue 10 | Original Article | 1122 | Copyright © October 2013
BACKGROUND: Little is known about the impact of long-term use of immunosuppressive agents on immune response.
OBJECTIVES: Assess the impact of continuous maintenance ustekinumab treatment on pa...
Read MoreCombination Use of Ustekinumab With Other Systemic Therapies: A Retrospective Study in a Tertiary Referral Center
October 2013 | Volume 12 | Issue 10 | Original Article | 1098 | Copyright © October 2013
BACKGROUND: Patients with moderate to severe psoriasis may not respond adequately to single systemic agent and may require combination systemic therapy.
OBJECTIVE: To evaluate the prevalence, i...
Read MoreAdherence to Ustekinumab in Psoriasis Patients
October 2013 | Volume 12 | Issue 10 | Original Article | 1090 | Copyright © October 2013
BACKGROUND: Adherence to the treatment of psoriasis is poor and effects treatment outcomes. Literature on adherence to biologic therapy for the treatment of psoriasis is limited and difficult to measu...
Read MoreInfliximab-Induced Psoriasis in Treatment of Crohn's Disease-Associated Ankylosing Spondylitis: Case Report and Review of 142 Cases
August 2013 | Volume 12 | Issue 8 | Original Article | 939 | Copyright © August 2013
TNF-alpha inhibitors are used to treat numerous inflammatory conditions including rheumatoid arthritis and inflammatory bowel disease. Recent reports have illustrated the paradoxical development of ps...
Read MoreAssociation Between the Type and Length of Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis
August 2013 | Volume 12 | Issue 8 | Original Article | 899 | Copyright © August 2013
OBJECTIVE: We sought to assess whether the type of TNF inhibitor therapy (soluble receptor versus monoclonal antibody) has an effect on MI risk; and determine whether length of TNF inhibitor therapy h...
Read MoreEffect of Infliximab on Health-Related Quality of Life and Disease Activity by Body Region in Patients With Moderate-to-Severe Psoriasis and Inadequate Response to Etanercept: Results from the PSUNRISE Trial
August 2013 | Volume 12 | Issue 8 | Original Article | 874 | Copyright © August 2013
BACKGROUND: Treatment with tumor necrosis factor (TNF)-α antagonists is effective in patients with moderate-to-severe plaque psoriasis, including those with impaired health-related quality of life (...
Read MoreComparison of the Efficacy of Biologics Versus Conventional Systemic Therapies in the Treatment of Psoriasis at a Comprehensive Psoriasis Care Center
August 2013 | Volume 12 | Issue 8 | Original Article | 861 | Copyright © August 2013
BACKGROUND: The efficacy of biologic treatment for psoriasis has not been compared to that of conventional systemic therapies and phototherapy outside of clinical trial settings.
DESIGN: Retros...
Read MoreResident Rounds. Part III A. Serendipitous Improvement in Moderate to Severe Acne in Psoriasis Patients Treated With Ustekinumab: A Two-Case Series
June 2013 | Volume 12 | Issue 6 | Features | 710 | Copyright © June 2013
Infections Associated With the Use of Tumor Necrosis Factor-α Inhibitors in Psoriasis
March 2013 | Volume 12 | Issue 3 | Original Article | 41 | Copyright © March 2013
Tumor necrosis factor (TNF)-α inhibitors have been shown to increase the risks of overall infection and serious infection in rheumatoid arthritis. However, it is uncertain whether we can draw th...
Read MoreThe Efficacy of Ustekinumab in Psoriasis
March 2013 | Volume 12 | Issue 3 | Original Article | 317 | Copyright © March 2013
Psoriasis is an immune-mediated cutaneous disease affecting 2% of the worldwide population. While topical therapy, phototherapy, oral systemic therapy, and biologic agents have been used, the treatmen...
Read MoreNew-Onset Vitiligo During Long-Term, Stable Infliximab Treatment of Pityriasis Rubra Pilaris
February 2013 | Volume 12 | Issue 2 | Case Reports | 217 | Copyright © February 2013
Incidents of new-onset vitiligo attributed to infliximab therapy for rheumatoid arthritis and ulcerative colitis have been reported. Reported cases share a common theme in that symptoms manifested in ...
Read MoreProgressive Multifocal Leukoencephalopathy and Reversible Progressive Leukoencephalopathy Syndrome in Dermatologic Therapy
February 2013 | Volume 12 | Issue 2 | Original Article | 20 | Copyright © February 2013
Progressive multifocal leukoencephalopathy (PML) is a frequently fatal demyelinating disease of the brain caused by activation of the John Cunningham virus. It typically occurs in immunocompromised pa...
Read MoreEfficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque-type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)
February 2013 | Volume 12 | Issue 2 | Original Article | 166 | Copyright © February 2013
Background: Available biologic agents for the treatment of psoriasis in China are limited.
Objectives: The LOTUS study is a phase 3, double-blind, placebo-controlled study that eva...
Read MoreTwo Cases of Hepatitis B in Patients With Moderate to Severe Psoriasis With Ustekinumab
December 2012 | Volume 11 | Issue 12 | Case Reports | 1498 | Copyright © December 2012
Background: Patients with psoriasis who are treated with systemic and biologic therapies may have an increased risk of infections, including hepatitis B virus (HBV). Cytokines that m...
Read MoreClearance of Nasal Staphylococcus aureus Colonization With Triple Antibiotic Ointment
December 2012 | Volume 11 | Issue 12 | Original Article | 1490 | Copyright © December 2012
Background: The prevalence of Staphylococcus aureus colonization of healthcare workers is reported at 30%, with colonization rates for methicillin-resistant S aureusRead More